Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults

NCT00387738 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

738

Enrollment

INDUSTRY

Sponsor class

Stopped Interim data indicated that subjects exhibited no meaningful allergic disease during the first ragweed season, making it impossible to measure treatment effect.

Conditions

Rhinitis, Allergic, Seasonal

Interventions

BIOLOGICAL: Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate
BIOLOGICAL: Histamine base

Sponsor

Dynavax Technologies Corporation